ホーム › トリプルネガティブ乳がん › アリゾナ州
アリゾナ州におけるトリプルネガティブ乳がんの臨床試験
アリゾナ州内の拠点で、トリプルネガティブ乳がんに関する18件の研究が参加者を募集しています。
アリゾナ州内の都市
公式研究テキスト（英語）
PRE-ISPY Phase I/II Oncology Platform Program
- Mayo Clinic Comprehensive Cancer Center, Phoenix
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05868226Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Ironwood Cancer & Research Centers ( Site 0036), Chandler
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Ironwood Cancer & Research Centers-Research ( Site 0054), Chandler
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Banner MD Anderson Cancer Center ( Site 0066), Gilbert
- Mayo Clinic Cancer Center ( Site 0034), Phoenix
- University of Arizona Cancer Center ( Site 0035), Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- HonorHealth Research Institute, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07705334Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Palo Verde Hematology Oncology, Glendale
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- HonorHealth, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
- Mayo Clinic in Arizona, Scottsdale
被験者募集中第2相
18歳以上 · 女性 · 2026/09/03更新 · NCT06635980Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR HonorHealth, Phoenix
- USOR Arizona Oncology Associates, Tucson
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Phoenix
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Mayo Clinic - Scottsdale, Scottsdale
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- HonorHealth Research and Innovation Institute, Scottsdale
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/29更新 · NCT06249048A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Banner MD Anderson Cancer Center, Gilbert
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/09更新 · NCT06682793A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Arizona Oncology Associates, Tucson
被験者募集中第2相
18歳以上 · 全性別 · 2025/06/19更新 · NCT06568692CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Arizona Oncology, Tucson
被験者募集中観察研究
18歳以上 · 女性 · 2025/01/07更新 · NCT06230185Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- HonorHealth Research Institute, Scottsdale
被験者募集中第1/2相
18歳以上 · 全性別 · 2024/11/15更新 · NCT04787042Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- HonorHealth Research Institute, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2024/02/08更新 · NCT04282044ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。